{
    "code": "10000835",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=10000835",
    "time": "2023-07-13 21:56:21",
    "許可證字號": "衛署菌疫輸字第000835號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "116\/04\/09",
    "發證\/登錄日期": "96\/04\/09",
    "許可證\/登錄種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA01000083501",
    "中文品名": "喜瑞樂凍晶注射劑150毫克",
    "英文品名": "Xolair 150 mg powder and solvent for solution for injection",
    "適應症": "1.過敏性氣喘附加療法：\r\n為附加療法用於改善已接受高劑量吸入性類固醇製劑及長效乙二型作用劑(ß2-agonist)治療下仍有頻繁之日間症狀或夜間覺醒且具有多次重度氣喘惡化記錄之重度持續過敏性氣喘成人、青少年及兒童(6歲及以上) 病人之氣喘控制。這些氣喘病人必須有經由皮膚測試或體外試驗顯示長期對空氣中過敏原呈陽性且肺功能降低 (FEV1 < 80%)。僅適用於證實為IgE媒介型之氣喘病人。\r\n2.慢性鼻竇炎併鼻息肉附加療法：\r\n適用於對鼻腔內皮質類固醇製劑治療無法達到適當的疾病控制之慢性鼻竇炎併鼻息肉成人(18歲以上)病人作為附加療法。\r\n適用於病人血清IgE濃度有相對應建議的投與劑量。\r\n3.慢性自發性蕁麻疹(Chronic Spontaneous Urticaria, CSU) 附加療法：\r\n適用於治療對H1抗組織胺製劑治療反應不佳之慢性自發性蕁麻疹成人及青少年(12歲及以上)病人作為附加療法。",
    "劑型": "243凍晶注射劑",
    "包裝": "150毫克(附2毫升溶劑)小瓶 100小瓶以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "OMALIZUMAB",
    "限制項目": "02輸　入",
    "申請商名稱": "台灣諾華股份有限公司",
    "申請商地址": "台北市中山區民生東路三段2號8樓",
    "主製造廠": [
        {
            "製造廠名稱": "NOVARTIS PHARMA STEIN AG",
            "製造廠廠址": "SCHAFFHAUSERSTRASSE CH-4332 STEIN, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "The Final Batch"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "裕利股份有限公司",
            "製造廠廠址": "桃園市大園區和平里1鄰開和路91號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        },
        {
            "製造廠名稱": "Delpharm Dijon",
            "製造廠廠址": "6, BLD DE L&#39;EUROPE 21800 QUETIGNY FRANCE",
            "製造廠公司地址": "",
            "製造廠國別": "FRANCE",
            "製程": "注射用水製造"
        },
        {
            "製造廠名稱": "NOVARTIS PHARMA S.A.S.",
            "製造廠廠址": "8, RUE DE L&#39;INDUSTRIE, F-68330 HUNINGUE, FRANCE",
            "製造廠公司地址": "",
            "製造廠國別": "FRANCE",
            "製程": "主成分(drug substance)製造廠"
        }
    ],
    "CCC號列": "30049020007 血液代用品與血漿代用品及基因重組製劑Substitutes of blood, substitutes of plasma and preparations  of gennetic recombinants",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013001300",
            "成分名稱": "OMALIZUMAB",
            "含量描述": "",
            "含量": "150.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "000835_Xolair 150 mg powder and solvent for solution for injection_2-108-06-24(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000835&Seq=002&Type=10"
        },
        {
            "title": "000835_Xolair 150 mg powder and solvent for solution for injection_1-108-06-24(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000835&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "喜瑞樂凍晶注射劑-TWI-240221-110-03-25.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000835&Seq=009&Type=9"
        },
        {
            "title": "2229827_TW_p1_FB_X-4-110-03-25.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000835&Seq=011&Type=8"
        },
        {
            "title": "2225444_TW_p1_LBL_X-4-110-03-25.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000835&Seq=010&Type=8"
        }
    ]
}